pharma · PPLPHARMA
Piramal Pharma
Piramal Pharma: ROTATIONAL regime.
Price
₹216.66
Price 2026-08-20
5 day
+4.85%
Short-term move
1 month
+17.23%
Medium-term
Regime
ROTATIONAL
68% confidence
Market cap
₹23.3k Cr
neutral sector flow
Market Intelligence Analyst
Understand today's market in about 2 minutes.
“How does today's ROTATIONAL regime affect Piramal Pharma (PPLPHARMA) in the pharma sector?”
Price chart
₹211
-0.31% over period
About Piramal Pharma
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing; offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain management drugs, and other generic and speciality products; and analgesics, skin care, vitamin and mineral supplement, kids' wellness, digestives, and women's health, as well as geriatric care. The company was incorporated in 2020 and is based in Mumbai, India.
At a Glance
RSI pattern warning
RSI oversold bounces for this stock succeeded only 0% of the time (avg -10.6% over 14 days) — not a reliable pattern.
52-week position
Trading at 98.1% of 52-week high
Technicals
RSI 14
72.6
Trend
uptrend
50 DMA
Above
200 DMA
Above
Key metrics
P/B
2.7
ROE
-400.0%
Below-average profitability — -400.0% ROE
Market cap
₹23.3k Cr
Revenue growth
-10.0% YoY
Promoter
54.5%
52-week range
₹132.3 – ₹220.85
98.1% of high
RSI (14)
72.6
uptrend
vs 50 DMA
Above
DMA ₹184.07
Coverage
89/100
HIGH
Quick Take
Piramal Pharma: ROTATIONAL regime.
Peer comparison
| Stock | Price | 5D | P/E | ROE | Rev growth | Mcap |
|---|---|---|---|---|---|---|
| DIVISLAB Divi's Laboratories | ₹8,570 | +0.8% | 70 | 16.2% | 950% | ₹1.8L Cr |
| CIPLA Cipla | ₹1,438 | -1.4% | 30.2 | 11.7% | -210% | ₹1.2L Cr |
| DRREDDY Dr. Reddy's Laboratories | ₹1,180 | -2.2% | 26.5 | 11.8% | -1160% | ₹1.1L Cr |
| AUROPHARMA Aurobindo Pharma | ₹1,608 | -3.3% | 26.3 | 9.9% | 560% | ₹91.1k Cr |
| ALKEM Alkem Laboratories | ₹5,400 | -0.9% | 29.4 | 17.6% | 1460% | ₹67.8k Cr |
| BIOCON Biocon | ₹412.5 | -1.8% | 145.3 | 1.1% | 230% | ₹66.3k Cr |
| GLENMARK Glenmark Pharmaceuticals | ₹2,332.9 | +0.6% | 47 | 14.1% | 1430% | ₹63.9k Cr |
| GLAND Gland Pharma | ₹2,820 | -5.0% | 40.9 | 10.5% | 2230% | ₹42.1k Cr |
| PPLPHARMA Piramal Pharma | ₹216.66 | +1.9% | N/A | -4% | -10% | ₹23.3k Cr |
Tensions to watch
Promoter holding at 54.5% — neither distress selling nor aggressive buying
No strong insider signal. Watch for changes in promoter stake as a leading indicator.
Key Watchpoints
Breaks above ₹227 (+5%)
Trend reversal confirmation
Breaks below ₹206 (-5%)
Further downside risk
Pharma sector entering leadership
Sector rotation signal
